Stratec SE Stock
€40.00
Your prediction
Stratec SE Stock
Pros and Cons of Stratec SE in the next few years
Pros
Cons
Performance of Stratec SE vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stratec SE | 0.250% | 1.656% | -6.228% | -35.749% | -13.072% | -64.690% | -35.332% |
| Eckert & Ziegler Strahlen- und Medizintechnik AG | -0.060% | -6.895% | -12.854% | -23.912% | -19.642% | -57.328% | 78.843% |
| Paul Hartmann AG | -1.430% | 1.942% | -4.977% | -7.895% | 2.439% | -46.015% | - |
| Geratherm Medical AG | -2.910% | -3.286% | -11.588% | -45.789% | -24.404% | -65.378% | -54.222% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, the financials of Stratec from the Healthcare Equipment & Supplies industry appear to be stable, experiencing growth in some areas while also facing certain challenges in others. The company has exhibited an upward trend in asset accumulation over the years, with total assets growing from 331.9 million EUR in 2020 to 397.5 million EUR in 2022. Additionally, Stratec has managed to maintain a healthy net income throughout this period.
Growth in Total Assets and Revenues: The total assets have seen growth over the years, increasing from 331.9 million EUR in 2020 to 397.5 million EUR in 2022. This is an indication that the company is consistently investing and expanding. Furthermore, Stratec experienced an increase in total revenues, from 250 million EUR in 2020 to 274.6 million EUR in 2022, reflecting positively on the company's financial performance.
Positive Net Income: Stratec has maintained a positive net income over the years, with the highest figure reached in 2021 at 39.9 million EUR. This shows that the company is profitable, which can help build investor confidence.
Comments
News
EQS-News: STRATEC REPORTS RESULTS FOR 2023 FINANCIAL YEAR
EQS-Adhoc: STRATEC PLANS TO DISTRIBUTE DIVIDEND OF € 0.55 PER SHARE FOR 2023 FINANCIAL YEAR
EQS-News: STRATEC TO PARTICIPATE IN THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE